BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 15708987)

  • 1. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
    J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
    Yi CE; Ba L; Zhang L; Ho DD; Chen Z
    J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus.
    Kitabatake M; Inoue S; Yasui F; Yokochi S; Arai M; Morita K; Shida H; Kidokoro M; Murai F; Le MQ; Mizuno K; Matsushima K; Kohara M
    Vaccine; 2007 Jan; 25(4):630-7. PubMed ID: 17011679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
    Bisht H; Roberts A; Vogel L; Bukreyev A; Collins PL; Murphy BR; Subbarao K; Moss B
    Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6641-6. PubMed ID: 15096611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
    Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM
    J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
    He Y; Zhou Y; Siddiqui P; Jiang S
    Biochem Biophys Res Commun; 2004 Dec; 325(2):445-52. PubMed ID: 15530413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
    Sui J; Li W; Roberts A; Matthews LJ; Murakami A; Vogel L; Wong SK; Subbarao K; Farzan M; Marasco WA
    J Virol; 2005 May; 79(10):5900-6. PubMed ID: 15857975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine design for severe acute respiratory syndrome coronavirus.
    He Y; Jiang S
    Viral Immunol; 2005; 18(2):327-32. PubMed ID: 16035944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
    He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
    Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.